Sorafenib Accord Union européenne - slovène - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Zaltrap Union européenne - slovène - EMA (European Medicines Agency)

zaltrap

sanofi winthrop industrie - aflibercept - kolorektalne neoplazme - antineoplastična sredstva - zdravljenje metastatskega kolorektalnega raka (mcrc).